SMN2 and spinal muscular atrophy, type 1: Treatment with SMN2 gene splice site modifier can prolong survival and enable the achievement of motor milestones in SMA type 1 patients [11, 12] and preserve motor functions in later onset SMA types 2 and 3 [13, 14].